Investigation of Vaccine Breakthrough Infections by Vaccine strategy during the Delta Variant Wave in France

Antonin Bal^{1,2} PharmD*, Grégory Destras^{1,2} PharmD*, Bruno Simon^{1,2} MD*, Jean-Marc
Giannoli³ PharmD, Florence Morfin^{1,2} PharmD PhD, Bruno Lina^{1,2} MD PhD, Laurence Josset
^{1,2} PharmD PhD, IVAC study group.

*equal contributions

¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon,
France.

²CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon,
Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-
69007, Lyon, France.

³DYOMEDEA-NEOLAB-Biogroup – Plateau technique de la Sauvegarde, Lyon, France

Corresponding authors: Antonin Bal

Associate Professor

University Hospital of Lyon, France

National reference center for respiratory viruses, Lyon, France

Phone: 04-72-07-16-98

Mail: antonin.bal@chu-lyon.fr

21 Abstract

22 Herein, we describe the characteristics of vaccine breakthrough infections (VBI) in fully
 23 vaccinated individuals according to five vaccine strategies during the Delta wave in France.
 24 Inclusion criterion was a positive test at least 2 weeks after a full vaccine schedule:
 25 homologous vaccination with Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273);
 26 heterologous vaccination with Astrazeneca and Pfizer-BioNTech (ChadOx1/BNT162b2);
 27 single-dose vaccines Johnson & Johnson (Ad26.COV2.S) or Astrazeneca (ChadOx1). A total
 28 of 1630 VBI from patients fully vaccinated between February and July were included in this
 29 study. SARS-CoV-2 sequencing performed for 1366 samples showed that the delta variant
 30 represented 94.1% (1286/1366). Delta-VBI were mainly symptomatic (mild symptoms) with
 31 no difference according to the vaccine strategy ($p=0.362$). The median RT-PCR Ct values at
 32 diagnosis were significantly different between symptomatic and asymptomatic cases only for
 33 BNT162b2 group (17.7 (15.07, 20.51) vs 19.00 (16.00, 23.00), $p=0.004$). Up to 50% of VBI
 34 was classified as early-VBI (infected less than one month after full immunization) for
 35 BNT162b2, mRNA-1273, ChadOx1, and J Ad26.COV2.S. People aged 14-49 yo were
 36 overrepresented in early VBI compared to non-early VBI for BNT162b2 and mRNA-1273
 37 (73.92% vs 37.87% for BNT162b2 and 77.78% vs 46.67 % for mRNA-1273, $p<0.05$). Our
 38 data emphasize a high prevalence of Delta-VBI occurring only one month after full
 39 immunization in young patients that might be related to relaxation of barrier gestures.

40 As of 29 November 2021, more than 89% of the adult population was fully vaccinated with
41 different vaccine strategies in France ¹. During this campaign, Delta vaccine breakthrough
42 infections (VBI) associated with a high viral load have been reported ². Furthermore, level and
43 duration of humoral and cellular immune responses was shown to be different according to
44 the vaccine used ^{3,4}. Herein, we describe the characteristics of VBI in fully vaccinated
45 individuals according to five vaccine strategies during the Delta wave in France.

46 An observational study was conducted at the national reference center for respiratory viruses
47 in Lyon, France from April 2021 to August 2021. During this period, samples positive for
48 SARS-CoV-2 in Biogroup community testing laboratories were retrieved for whole genome
49 sequencing. Inclusion criterion was a positive test at least 2 weeks after a full vaccine
50 schedule: homologous vaccination with Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-
51 1273); heterologous vaccination with Astrazeneca and Pfizer-BioNTech
52 (ChadOx1/BNT162b2); single-dose vaccines Johnson & Johnson (Ad26.COV2.S) or
53 Astrazeneca (ChadOx1).

54 Ethics approval was obtained from the national review board for biomedical research (Comité
55 de Protection des Personnes Centre-Ouest I, France; ID-RCB 2021-A01877-34), and the
56 study was registered on ClinicalTrials.gov (NCT05060939). Continuous variables are
57 presented as median with interquartile range (IQR) and compared using non-parametric
58 Kruskal–Wallis tests. Proportions were compared using the chi-squared or Fisher's exact test
59 as appropriate. A p-value of <0.05 was regarded as statistically significant. Statistical
60 analyses were conducted using R software, version 4.0.5 (R Foundation for Statistical
61 Computing).

62 A total of 1630 VBI from patients fully vaccinated between February and July were included
63 in this study. SARS-CoV-2 sequencing performed for 1366 samples showed that the delta
64 variant represented 94.1% (1286/1366) of VBI (Figure 1A).

65 Among delta-VBI, BNT162b2 was the most frequent vaccine reported (1017/ 79.1%) followed
66 by ChadOx1 (118/1286, 9.2%) and mRNA-1273 (90/1286, 7.0%, Table). The number of VBI
67 in each age group followed the dynamics of SARS-CoV-2 infections in France with a peak
68 occurring in mid-August (Figure 1B). The median age of Delta-VBI cases significantly
69 differed depending on the vaccine strategy with a median below 50 yo except for
70 Ad26.COV2.S and ChadOx1 groups (p<0.001). Delta-VBI were mainly symptomatic (mild
71 symptoms) with no difference according to the vaccine strategy (p=0.362). The median RT-
72 PCR Ct values at diagnosis were significantly different between symptomatic and
73 asymptomatic cases only for BNT162b2 group (17.7 (15.07, 20.51) vs 19.00 (16.00, 23.00),
74 p=0.004).

75

76 Interestingly, more than 75% of Delta-VBI occurred in patients who were within three months
77 following full immunization, regardless of the vaccination strategy. Besides, up to 50% of VBI
78 was classified as early-VBI (infected less than one month after full immunization) for
79 BNT162b2, mRNA-1273, ChadOx1, and J Ad26.COV2.S (Table). People aged 14-49 yo
80 were overrepresented in early VBI compared to non-early VBI for BNT162b2 and mRNA-
81 1273 (73.92% vs 37.87% for BNT162b2 and 77.78% vs 46.67 % for mRNA-1273, $p < 0.05$,
82 Figure 1).

83 Our data showed that mild VBI detected in community laboratories during the spread of Delta
84 mainly occurred within three months after full immunization for all vaccine strategies. Low Ct
85 values and presence of symptoms observed herein support a risk of transmission as
86 previously noted in fully vaccinated health care workers infected by Delta variant ⁵.

87 The main limitations of this study are related to the French vaccine policies explaining the
88 limited sample sizes for non-RNA vaccines and differences in vaccination date between age
89 groups and vaccine types. Yet our data emphasize a high prevalence of Delta-VBI occurring
90 only one month after full immunization in young patients that might be related to relaxation of
91 barrier gestures. The surveillance of VBI should be reinforced in the context of the booster
92 vaccination campaign.

93 **Table. Characteristics of Delta vaccine breakthrough infections in fully vaccinated individuals by**
94 **vaccine strategy**

	Astrazeneca (ChadOx1) N = 118	Astrazeneca/ Pfizer (ChadOx1/BNT162b2) N = 24	Johnson & Johnson (Ad26.COV2.S) N = 37	Moderna (mRNA-1273) N = 90	Pfizer- BioNTech (BNT162b2) N = 1017	Total N = 1,286	p
Symptomatic							
n (%)	50/72 (69.44%)	18/21 (85.71%)	19/26 (73.08%)	40/54 (74.07%)	506/626 (80.83%)	633/799 (79.22%)	0.127
Ct at diagnosis							
symptomatic, median (IQR)	17.30 (14.33, 20.00) N=47	19.60 (15.13, 22.00) N=17	16.55 (14.59, 21.90) N=19	18.50 (15.34, 22.50) N=37	17.74 (15.07, 20.51) N= 358	17.74 (15.00, 21.00) N=478	0.362
asymptomatic, median (IQR)	18.47 (16.00, 20.15) N=22	18.30 (18.25, 19.65) N=3	19.30 (17.05, 22.09) N=7	21.88 (19.85, 23.12) N=14	19.00 (16.00, 23.00) N=90	19.55 (16.00, 23.00) N=136	0.382
p.value	0.141	0.681	0.523	0.187	0.004	0	
Comorbidities							
n (%)	29/54 (53.70%)	4/8 (50.00%)	0/3 (0.00%)	10/36 (27.78%)	108/402 (26.87%)	151/503 (30.02%)	0.001
Sex							
Female n (%)	65 (55.08%)	16 (66.67%)	18 (48.65%)	47 (52.22%)	590 (58.01%)	736 (57.23%)	0.496
Age							
median (IQR)	62.00 (58.00, 68.00)	45.00 (36.75, 53.00)	57 (43.00, 62.00)	41.00 (26.25, 57.00)	46 (32.00, 61.00)	49.00 (34.00, 62.75)	p<0.001
Time between full immunization and positive PCR							
All, median days (IQR)	45.00 (21.25, 56.75)	44.00 (36.00, 60.25)	35.00 (6.00, 54.00)	30.50 (10.00, 82.00)	30.00 (11.00, 73.00)	33.00 (12.00, 70.00)	0.171
14-49yo, median days (IQR)	63.00 (37.00, 73.50)	57 (53.00, 74.00)	45.00 (20.50, 66.00)	34.00 (14.75, 80.25)	33.00 (19.00, 54.00)	34 (19.00, 59.00)	0.007
50-64yo, median days (IQR)	59.00 (33.00, 69.25)	58.50 (47.75, 73.00)	65 (19.00, 94.00)	65.00 (31.00, 91.75)	49.50 (32.75, 87.00)	52 (33.00, 82.00)	0.682
>64, median days (IQR)	46; 58.00 (41.00, 71.00)	132 (132.00, 132.00)	56.50 (42.75, 68.00)	111.00 (66.00, 150.75)	90.50 (56.00, 124.00)	84 (53.00, 118.00)	0
Cumulative breakthrough cases within							
1 month n (%)	43 (36.44%)	2 (8.33%)	15 (40.54%)	45 (50.00%)	510 (50.15%)	615 (47.82%)	0
2 months n (%)	95 (80.51%)	18 (75.00%)	29 (78.38%)	54 (60.00%)	714 (70.21%)	910 (70.76%)	0.018
3 months n (%)	113 (95.76%)	23 (95.83%)	34 (91.89%)	71 (78.89%)	846 (83.19%)	1,087 (84.53%)	0.001
4 months n (%)	116 (98.31%)	24 (100.00%)	34 (91.89%)	78 (86.67%)	920 (90.46%)	1,172 (91.14%)	0.013
5 months n (%)	118 (100.00%)	24 (100.00%)	34 (91.89%)	88 (97.78%)	979 (96.26%)	1,243 (96.66%)	0.08
6 months n (%)	118 (100.00%)	24 (100.00%)	36 (97.30%)	90 (100.00%)	1,013 (99.61%)	1,281 (99.61%)	0.198

Figure caption

NGS-confirmed vaccine breakthrough infections in fully vaccinated individuals, April, 12th to August, 30th

A. Vaccine breakthrough infections (VBI) are represented by vaccine strategy and by age group. The delay since full immunization are represented in the y-axis. The horizontal dotted lines indicate the delay of one month following the full immunization. VBI represented below these lines are defined as early VBI. Each Pango lineage determined by whole genome sequencing is represented by a symbol. Lineage B.1.617.2 (Delta variant) is represented in red. B. Incidence of COVID-19 cases in France is represented by age group ⁶.

References

1. info coronavirus Covid 19 - Vaccins. Gouvernement.fr. Accessed November 27, 2021. <https://www.gouvernement.fr/info-coronavirus/vaccins>
2. Blanquart F, Abad C, Ambroise J, et al. Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. *Eurosurveillance*. 2021;26(37):2100824. doi:10.2807/1560-7917.ES.2021.26.37.2100824
3. Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines | NEJM. Accessed November 27, 2021. <https://www.nejm.org/doi/full/10.1056/NEJMc2115596>
4. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. *Nature*. Published online October 21, 2021:1-9. doi:10.1038/s41586-021-04120-y
5. Kemp SA, Cheng MT, Hamilton W, et al. *Transmission of B.1.617.2 Delta Variant between Vaccinated Healthcare Workers.*; 2021:2021.11.19.21266406. doi:10.1101/2021.11.19.21266406
6. Taux d'incidence de l'épidémie de COVID-19 (SI-DEP) - data.gouv.fr. Accessed November 27, 2021. <https://www.data.gouv.fr/fr/datasets/taux-d-incidence-de-lepidemie-de-covid-19/>

IVAC study group

Quentin Semanas, Antoine Oblette, Hadrien Regue, Geneviève Billaud, Martine Valette, Sophie Assant, Mary-Anne Trabaud, Bruno Pozzetto